Worldwide differences in regulations of clozapine use

Jimmi Nielsen, Corina Young, Petru Ifteni, Taishiro Kishimoto, Yu Tao Xiang, Peter F J Schulte, Christoph U. Correll, David Taylor

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Clozapine remains the drug of choice for treatment-resistant schizophrenia. As a consequence of its long history and complex pharmacology, we suspected wide variation in the regulations of clozapine use across different countries. The summaries of product characteristics (SPCs) from clozapine manufacturers, as well as local and national guidelines in the following selected countries, were reviewed: China, Denmark, Ireland, Japan, The Netherlands, New Zealand, Romania, the UK and the US. Clozapine is available as tablets in all countries, as an oral suspension in all included countries, with the exception of Japan and Romania, as orally disintegrating tablets in the US and China, and as an injectable in The Netherlands. General practitioner prescribing is only available in The Netherlands, New Zealand, the UK and the US, although with some restrictions in some of the countries. In Ireland and China, clozapine is only dispensed through hospital pharmacies. Hematological monitoring is mandatory in all countries but varies substantially in frequency, e.g. in Denmark hematologic monitoring is mandatory weekly for 18 weeks, followed by monthly monitoring, compared with Japan where blood work is required weekly for 26 weeks, followed by biweekly hematologic monitoring thereafter. In most included countries, with the exception of Denmark, Romania and The Netherlands, The manufacturer provides a mandatory hematological monitoring database, and dispensing of clozapine is not permissible without acceptable white blood count and absolute neutrophil count results. Local guidelines in New Zealand recommend echocardiography and routine troponin during the initial phases of treatment with clozapine. Regulations of clozapine vary widely with regard to rules of prescribing and monitoring. A worldwide update and harmonization of these regulations is recommended.

Original languageEnglish
Pages (from-to)149-161
Number of pages13
JournalCNS Drugs
Volume30
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Clozapine
Netherlands
Romania
Denmark
New Zealand
China
Japan
Ireland
Tablets
Guidelines
Troponin
Pharmacies
General Practitioners
Echocardiography
Schizophrenia
Suspensions
Neutrophils
History
Databases
Pharmacology

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Nielsen, J., Young, C., Ifteni, P., Kishimoto, T., Xiang, Y. T., Schulte, P. F. J., ... Taylor, D. (2016). Worldwide differences in regulations of clozapine use. CNS Drugs, 30(2), 149-161. https://doi.org/10.1007/s40263-016-0311-1

Worldwide differences in regulations of clozapine use. / Nielsen, Jimmi; Young, Corina; Ifteni, Petru; Kishimoto, Taishiro; Xiang, Yu Tao; Schulte, Peter F J; Correll, Christoph U.; Taylor, David.

In: CNS Drugs, Vol. 30, No. 2, 01.02.2016, p. 149-161.

Research output: Contribution to journalArticle

Nielsen, J, Young, C, Ifteni, P, Kishimoto, T, Xiang, YT, Schulte, PFJ, Correll, CU & Taylor, D 2016, 'Worldwide differences in regulations of clozapine use', CNS Drugs, vol. 30, no. 2, pp. 149-161. https://doi.org/10.1007/s40263-016-0311-1
Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang YT, Schulte PFJ et al. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016 Feb 1;30(2):149-161. https://doi.org/10.1007/s40263-016-0311-1
Nielsen, Jimmi ; Young, Corina ; Ifteni, Petru ; Kishimoto, Taishiro ; Xiang, Yu Tao ; Schulte, Peter F J ; Correll, Christoph U. ; Taylor, David. / Worldwide differences in regulations of clozapine use. In: CNS Drugs. 2016 ; Vol. 30, No. 2. pp. 149-161.
@article{17877be3de974f2ba00ecceb379d0414,
title = "Worldwide differences in regulations of clozapine use",
abstract = "Clozapine remains the drug of choice for treatment-resistant schizophrenia. As a consequence of its long history and complex pharmacology, we suspected wide variation in the regulations of clozapine use across different countries. The summaries of product characteristics (SPCs) from clozapine manufacturers, as well as local and national guidelines in the following selected countries, were reviewed: China, Denmark, Ireland, Japan, The Netherlands, New Zealand, Romania, the UK and the US. Clozapine is available as tablets in all countries, as an oral suspension in all included countries, with the exception of Japan and Romania, as orally disintegrating tablets in the US and China, and as an injectable in The Netherlands. General practitioner prescribing is only available in The Netherlands, New Zealand, the UK and the US, although with some restrictions in some of the countries. In Ireland and China, clozapine is only dispensed through hospital pharmacies. Hematological monitoring is mandatory in all countries but varies substantially in frequency, e.g. in Denmark hematologic monitoring is mandatory weekly for 18 weeks, followed by monthly monitoring, compared with Japan where blood work is required weekly for 26 weeks, followed by biweekly hematologic monitoring thereafter. In most included countries, with the exception of Denmark, Romania and The Netherlands, The manufacturer provides a mandatory hematological monitoring database, and dispensing of clozapine is not permissible without acceptable white blood count and absolute neutrophil count results. Local guidelines in New Zealand recommend echocardiography and routine troponin during the initial phases of treatment with clozapine. Regulations of clozapine vary widely with regard to rules of prescribing and monitoring. A worldwide update and harmonization of these regulations is recommended.",
author = "Jimmi Nielsen and Corina Young and Petru Ifteni and Taishiro Kishimoto and Xiang, {Yu Tao} and Schulte, {Peter F J} and Correll, {Christoph U.} and David Taylor",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s40263-016-0311-1",
language = "English",
volume = "30",
pages = "149--161",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Worldwide differences in regulations of clozapine use

AU - Nielsen, Jimmi

AU - Young, Corina

AU - Ifteni, Petru

AU - Kishimoto, Taishiro

AU - Xiang, Yu Tao

AU - Schulte, Peter F J

AU - Correll, Christoph U.

AU - Taylor, David

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Clozapine remains the drug of choice for treatment-resistant schizophrenia. As a consequence of its long history and complex pharmacology, we suspected wide variation in the regulations of clozapine use across different countries. The summaries of product characteristics (SPCs) from clozapine manufacturers, as well as local and national guidelines in the following selected countries, were reviewed: China, Denmark, Ireland, Japan, The Netherlands, New Zealand, Romania, the UK and the US. Clozapine is available as tablets in all countries, as an oral suspension in all included countries, with the exception of Japan and Romania, as orally disintegrating tablets in the US and China, and as an injectable in The Netherlands. General practitioner prescribing is only available in The Netherlands, New Zealand, the UK and the US, although with some restrictions in some of the countries. In Ireland and China, clozapine is only dispensed through hospital pharmacies. Hematological monitoring is mandatory in all countries but varies substantially in frequency, e.g. in Denmark hematologic monitoring is mandatory weekly for 18 weeks, followed by monthly monitoring, compared with Japan where blood work is required weekly for 26 weeks, followed by biweekly hematologic monitoring thereafter. In most included countries, with the exception of Denmark, Romania and The Netherlands, The manufacturer provides a mandatory hematological monitoring database, and dispensing of clozapine is not permissible without acceptable white blood count and absolute neutrophil count results. Local guidelines in New Zealand recommend echocardiography and routine troponin during the initial phases of treatment with clozapine. Regulations of clozapine vary widely with regard to rules of prescribing and monitoring. A worldwide update and harmonization of these regulations is recommended.

AB - Clozapine remains the drug of choice for treatment-resistant schizophrenia. As a consequence of its long history and complex pharmacology, we suspected wide variation in the regulations of clozapine use across different countries. The summaries of product characteristics (SPCs) from clozapine manufacturers, as well as local and national guidelines in the following selected countries, were reviewed: China, Denmark, Ireland, Japan, The Netherlands, New Zealand, Romania, the UK and the US. Clozapine is available as tablets in all countries, as an oral suspension in all included countries, with the exception of Japan and Romania, as orally disintegrating tablets in the US and China, and as an injectable in The Netherlands. General practitioner prescribing is only available in The Netherlands, New Zealand, the UK and the US, although with some restrictions in some of the countries. In Ireland and China, clozapine is only dispensed through hospital pharmacies. Hematological monitoring is mandatory in all countries but varies substantially in frequency, e.g. in Denmark hematologic monitoring is mandatory weekly for 18 weeks, followed by monthly monitoring, compared with Japan where blood work is required weekly for 26 weeks, followed by biweekly hematologic monitoring thereafter. In most included countries, with the exception of Denmark, Romania and The Netherlands, The manufacturer provides a mandatory hematological monitoring database, and dispensing of clozapine is not permissible without acceptable white blood count and absolute neutrophil count results. Local guidelines in New Zealand recommend echocardiography and routine troponin during the initial phases of treatment with clozapine. Regulations of clozapine vary widely with regard to rules of prescribing and monitoring. A worldwide update and harmonization of these regulations is recommended.

UR - http://www.scopus.com/inward/record.url?scp=84959893294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959893294&partnerID=8YFLogxK

U2 - 10.1007/s40263-016-0311-1

DO - 10.1007/s40263-016-0311-1

M3 - Article

C2 - 26884144

AN - SCOPUS:84959893294

VL - 30

SP - 149

EP - 161

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 2

ER -